X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ELDER PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ELDER PHARMA GLENMARK PHARMA/
ELDER PHARMA
 
P/E (TTM) x 13.5 -0.2 - View Chart
P/BV x 3.8 0.1 3,749.6% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
ELDER PHARMA
Jun-14
GLENMARK PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,262380 332.1%   
Low Rs672188 357.2%   
Sales per share (Unadj.) Rs270.6491.2 55.1%  
Earnings per share (Unadj.) Rs24.9-3.2 -781.9%  
Cash flow per share (Unadj.) Rs34.414.4 238.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs151.3376.5 40.2%  
Shares outstanding (eoy) m282.1620.54 1,373.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.60.6 618.0%   
Avg P/E ratio x38.9-89.3 -43.5%  
P/CF ratio (eoy) x28.119.7 142.5%  
Price / Book Value ratio x6.40.8 846.9%  
Dividend payout %8.00-   
Avg Mkt Cap Rs m272,7785,833 4,676.2%   
No. of employees `00010.0NA-   
Total wages/salary Rs m13,7822,179 632.5%   
Avg. sales/employee Rs Th7,614.9NM-  
Avg. wages/employee Rs Th1,374.8NM-  
Avg. net profit/employee Rs Th700.2NM-  
INCOME DATA
Net Sales Rs m76,34010,089 756.7%  
Other income Rs m356257 138.8%   
Total revenues Rs m76,69610,346 741.3%   
Gross profit Rs m14,172-792 -1,789.6%  
Depreciation Rs m2,691361 744.9%   
Interest Rs m1,7892,756 64.9%   
Profit before tax Rs m10,048-3,653 -275.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m3,028125 2,419.8%   
Profit after tax Rs m7,019-65 -10,740.8%  
Gross profit margin %18.6-7.8 -236.5%  
Effective tax rate %30.1-3.4 -879.8%   
Net profit margin %9.2-0.6 -1,419.5%  
BALANCE SHEET DATA
Current assets Rs m59,0969,240 639.6%   
Current liabilities Rs m40,0189,998 400.3%   
Net working cap to sales %25.0-7.5 -332.8%  
Current ratio x1.50.9 159.8%  
Inventory Days Days7546 161.9%  
Debtors Days Days11960 198.8%  
Net fixed assets Rs m39,07510,124 386.0%   
Share capital Rs m282206 137.2%   
"Free" reserves Rs m30,2815,582 542.5%   
Net worth Rs m42,7037,734 552.2%   
Long term debt Rs m24,8734,889 508.8%   
Total assets Rs m111,02622,882 485.2%  
Interest coverage x6.6-0.3 -2,034.0%   
Debt to equity ratio x0.60.6 92.1%  
Sales to assets ratio x0.70.4 155.9%   
Return on assets %7.911.8 67.5%  
Return on equity %16.4-0.8 -1,945.2%  
Return on capital %17.522.3 78.5%  
Exports to sales %43.33.0 1,424.3%   
Imports to sales %7.40.4 1,739.3%   
Exports (fob) Rs m33,044307 10,777.4%   
Imports (cif) Rs m5,67243 13,160.8%   
Fx inflow Rs m36,945307 12,049.8%   
Fx outflow Rs m61,066125 48,736.0%   
Net fx Rs m-24,122181 -13,304.7%   
CASH FLOW
From Operations Rs m3,44911,754 29.3%  
From Investments Rs m-8,802-561 1,570.3%  
From Financial Activity Rs m6,986-6,762 -103.3%  
Net Cashflow Rs m9344,432 21.1%  

Share Holding

Indian Promoters % 48.3 39.6 122.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.5 92.0%  
FIIs % 34.4 16.8 204.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 36.1 29.1%  
Shareholders   56,727 16,479 344.2%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS